Why Trials Matter Right Now in the UK
The pressure on UK diabetes care has never been more visible. Millions of adults live with type 2 diabetes, and the cost of type 1 diabetes alone is estimated at around £1.9 billion a year for the NHS. Waiting lists stretch in some regions, and many people find themselves on a medication routine that feels harder to manage each year, not easier.
Three patterns come up again and again in conversations with people living with diabetes. Weight gain alongside blood sugar problems, where each makes the other worse. A psychological load that clinics rarely have time to address. And a sense that the treatments on offer are the same ones prescribed years ago. Trials are one answer to all three, because they give people early access to approaches that may not reach standard care for some time.
The good news is that the UK has a strong research network. The national registry lists hundreds of recruiting studies across 140 or more cities, from Birmingham and Bristol to Blackpool and Newcastle. Universities such as Ulster, Surrey, Oxford Brookes and Imperial College London are running their own studies, alongside NHS trusts and commercial sponsors.
The NHS Remission Programme: Real Results at Scale
The clearest example of research moving into everyday care is the NHS Type 2 Diabetes Path to Remission Programme, run jointly with Diabetes UK. More than 13,000 people signed up last year alone. The model is simple but demanding: 12 weeks of low-calorie total diet replacement, roughly 800 to 900 calories a day in the form of soups and shakes, followed by a gradual reintroduction of food.
Early data shows participants losing over 10kg on average, with improved blood sugar and reduced diabetes medication. In almost half of participants, type 2 diabetes went into remission. That is not a small outcome. It changes the conversation from managing a lifelong condition to potentially reversing it.
Helen, a 52-year-old teaching assistant from Sheffield, described the first week as brutal. "By week three the cravings faded. By the end I was checking my results at the clinic and my nurse nearly cried." Her story reflects the pattern seen in the national data, though not everyone achieves remission. Eligibility depends on factors like body mass index, and the programme is offered where NHS England commissions it.
New Medications on the Horizon
For people whose blood sugar remains above target despite current treatment, several trials are testing the next generation of medication. The TRANSCEND-T2D programme published phase 3 results earlier this year in The Lancet for retatrutide, a drug that acts on three gut hormones at once. Findings showed meaningful reductions in HbA1c alongside weight loss, which is why the BMJ reported it as a significant step for type 2 diabetes management.
A separate phase 2 study sponsored by Eli Lilly is recruiting in Birmingham, Blackpool, Bristol, Bromborough and Newcastle, testing a new compound against placebo in people already on a stable dose of semaglutide or tirzepatide. And a study based in London is examining whether a GLP-1 medicine can prevent steroid-induced diabetes in people with prediabetes.
What Participation Really Looks Like
| Trial or programme | Focus | Costs to participant | Best suited to | Main benefits | Points to weigh up |
|---|
| NHS Path to Remission | Total diet replacement | Covered where eligible | Adults with type 2 and overweight or obesity | Around 10kg loss, remission in nearly half | 12 weeks of shakes and soups, strict routine |
| TRANSCEND-T2D (retatrutide) | Triple hormone medication | Study-related care provided | People with type 2 above glucose target | HbA1c reduction plus weight loss | Injections and repeated clinic visits |
| New mealtime insulin study | Experimental fast-acting insulin | £180 plus travel expenses reimbursed | People already on insulin therapy | Fewer hypoglycaemic episodes, less weight gain | Appointments spread over several months |
| INGR1D2 type 1 prevention | Genetic screening for babies | Covered for participating families | Families with babies under six weeks | Early detection of type 1 risk | Only at participating hospital sites |
| UWE Bristol digital wellbeing study | Self-guided online programme | None to participants | Adults with type 1 or type 2 | Lower diabetes distress | Online only, no medical treatment |
A trial of a new mealtime insulin based in London offers £180 across two payments plus travel reimbursement, with all study medications and ophthalmology checks provided. That pattern is typical. Sponsors generally cover study-related care and reimburse reasonable travel, which makes participation viable for people on lower incomes.
Type 1 Research: Prevention and a Possible Shift
Type 1 diabetes gets less media attention than the type 2 remission story, but progress is real. At Addenbrooke's in Cambridge, the INGR1D2 trial offers genetic screening to families with babies under six weeks old. Where screening shows high risk, families can be invited to receive a vaccine aimed at preventing the condition. The lead researcher describes the potential to improve long-term health for thousands of children and to save the NHS substantial future costs.
Elsewhere, work on beta cell therapy is moving toward transplantation without lifelong immunosuppression. Early results from a first-in-human study suggest donor cells can be altered in the lab so the immune system is less likely to reject them. These findings are preliminary, but they point toward a future where some people with type 1 might manage without constant insulin.
The Psychological Side of Management
Not every trial involves injections or shakes. Researchers at the University of the West of England are recruiting adults with type 1 or type 2 for a four-week digital programme designed to support emotional wellbeing, combining psychological techniques with behaviour change methods. Another study at the University of Surrey is gathering experiences from people with both type 2 diabetes and depression who have used NHS Talking Therapies. And an Oxford Brookes project is testing whether beetroot juice can improve cardiovascular recovery after exercise in people aged 40 to 65.
These studies matter because diabetes distress is one of the most commonly reported barriers to consistent self-management. A person who feels burned out by daily monitoring is less likely to keep appointments or adjust their routine. Research that treats the emotional side as seriously as the metabolic side reflects a shift in how clinicians think about the condition.
How to Find and Join a Study
- Start with the Diabetes UK clinical trials page, which lists active studies with contact details for each research team.
- Search ClinicalTrials.gov and the ISRCTN registry, filtering by condition and UK location.
- Ask your GP or diabetes team whether they know of local recruiting studies, since many sites are embedded in NHS trusts.
- Read the eligibility criteria carefully before contacting the team, as criteria such as age, HbA1c range and BMI are usually strict.
- Speak with your usual clinician before consenting, so you understand how trial participation interacts with your existing care.
Regional resources are genuinely strong. Northern Ireland's Ulster University is running an omega-3 study for people with prediabetes or type 2, while London hosts the GAPSID trial and the new insulin study. Scotland and Wales have their own research networks connected to the same national registries, so geography rarely needs to be a barrier.
A Decision Worth Making Carefully
Joining a trial is a personal decision, not a step everyone needs to take. Some people find the commitment of clinic visits and extra monitoring burdensome, and that is a fair response. Others describe participation as the first time in years they felt actively involved in their own care, with a research team who had time to explain every number.
If you live with diabetes in the UK and are curious about what research could offer you, the practical move is simple. Open the Diabetes UK trials page, search for your condition and your region, and send a short message to a study team that looks relevant. The worst outcome is that you are not eligible. The best outcome might be a treatment that changes the course of your condition, or at least a clearer sense of what the next few years of diabetes care could look like.
研究の知恵